Disease Overview Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections. Urothelial carcinoma, also known as transitional cell carcinoma, accounts for over 90% of bladder cancers. Approximately three-quarters of urothelial carcinoma patients initially present with non-muscle invasive bladder cancer (NMIBC), which is associated with a relatively good prognosis. However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.
The value of the bladder cancer market is projected to reach $4.8bn by 2025, with growth driven by immunotherapies. Pharmacological treatment of urothelial bladder cancer is dominated by platinum-based chemotherapy regimens. Between 2017 and 2037, incident cases of bladder cancer will increase by over 40% in the US, Japan, and five major EU markets. Immunotherapy developers will seek label expansions in a variety of treatment settings to differentiate their products. Late-phase targeted therapies will look to address needs not met by immunotherapies.
Our reports have been used by over 10K customers, including:
The global cell counting market grew at a CAGR of around 6% during 2015-2020. Looking forward, the analyst expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
120 pages •
By Infiniti Research Limited
• Dec 2021
Global Aptamers Market 2022-2026 The analyst has been monitoring the aptamers market and it is poised to grow by $ 1.31 bn during 2022-2026, progressing at a CAGR of 27.70% during the forecast period. Our report on the aptamers market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges,...
120 pages •
By Infiniti Research Limited
• Nov 2021
Global Liposomal Products Market 2022-2026 The analyst has been monitoring the liposomal products market and it is poised to grow by $ 2213.73 million during 2022-2026, progressing at a CAGR of 7.81% during the forecast period. Our report on the liposomal products market provides a holistic analysis, market size and forecast,...
INTRODUCTION According to the World Health Organization, in a year, around 2 million to 3 million individuals suffer from various forms of skin cancers, across the globe. This type of cancer account for 33% of all the diagnosed tumors, globally. It is also worth highlighting that one in every five Americans is likely to...
178 pages •
By Roots Analysis Private Ltd.
• Oct 2021
INTRODUCTION According to the World Health Organization (WHO), at present, cancer is the second leading cause of death, worldwide. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with various types of cancer, in the US alone. As a result of the growing...
274 pages •
By Global Industry Analysts
• Jan 2022
Abstract: Global DNA Sequencing Market to Reach US$10.1 Billion by the Year 2026 Deoxyribonucleic acid (DNA) sequencing involves process of determining sequence of four nucleotides bases namely, adenine, cytosine, guanine, and thymine present in DNA. The advanced technology assists healthcare...
Medulloblastoma (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma – Drugs In Development, 2021, provides an overview of the Medulloblastoma (Oncology) pipeline landscape. Medulloblastoma is the most common malignant...
Bile Duct Cancer (Cholangiocarcinoma) (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) – Drugs In Development, 2021, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.